Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2012 3
2013 1
2015 1
2017 1
2018 3
2019 6
2020 13
2021 16
2022 23
2023 20
2024 22
2025 54
2026 50

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean emt cancer immunotherapy (1,313 results)?
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Routy B, et al. Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2. Science. 2018. PMID: 29097494
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition. Antibiotics inhibited the clin …
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer …
Fecal microbiota transplantation: current challenges and future landscapes.
Yadegar A, Bar-Yoseph H, Monaghan TM, Pakpour S, Severino A, Kuijper EJ, Smits WK, Terveer EM, Neupane S, Nabavi-Rad A, Sadeghi J, Cammarota G, Ianiro G, Nap-Hill E, Leung D, Wong K, Kao D. Yadegar A, et al. Clin Microbiol Rev. 2024 Jun 13;37(2):e0006022. doi: 10.1128/cmr.00060-22. Epub 2024 May 8. Clin Microbiol Rev. 2024. PMID: 38717124 Free PMC article. Review.
In this review, we outline clinical applications, efficacy, durability, and safety of FMT and provide a comprehensive assessment of its procedural and administration aspects. The clinical applications of FMT in children and cancer immunotherapy are als …
In this review, we outline clinical applications, efficacy, durability, and safety of FMT and provide a comprehensive assessment of i …
Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy.
Singh A, Alexander SG, Martin S. Singh A, et al. Front Immunol. 2023 May 16;14:1114499. doi: 10.3389/fimmu.2023.1114499. eCollection 2023. Front Immunol. 2023. PMID: 37261348 Free PMC article. Review.
The gut microbiome has an impact on cancer immune surveillance and immunotherapy, with recent studies showing categorical differences between immunotherapy-sensitive and immunotherapy-resistant cancer patient cohorts. ...The gut microbiome's het …
The gut microbiome has an impact on cancer immune surveillance and immunotherapy, with recent studies showing categorical diff …
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B. Baruch EN, et al. Science. 2021 Feb 5;371(6529):602-609. doi: 10.1126/science.abb5920. Epub 2020 Dec 10. Science. 2021. PMID: 33303685 Clinical Trial.
The gut microbiome has been shown to influence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclinical mouse models and observational patient cohorts. However, modulation of gut microbiota in cancer patients has not been investigat …
The gut microbiome has been shown to influence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclin …
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer.
Wang X, Fang Y, Liang W, Wong CC, Qin H, Gao Y, Liang M, Song L, Zhang Y, Fan M, Liu C, Lau HC, Xu L, Li X, Song W, Wang J, Wang N, Yang T, Mo M, Zhang X, Fang J, Liao B, Sung JJY, Yu J. Wang X, et al. Cancer Cell. 2024 Oct 14;42(10):1729-1746.e8. doi: 10.1016/j.ccell.2024.08.019. Epub 2024 Sep 19. Cancer Cell. 2024. PMID: 39303724 Free article.
Fecal microbiota transplantation (FMT) from patients with Fn-high MSS CRC to germ-free mice bearing MSS CRC confers sensitivity to anti-PD-1 compared to FMT from Fn-low counterparts. ...In patients with MSS CRC, high intratumoral Fn predicts favorable response to an …
Fecal microbiota transplantation (FMT) from patients with Fn-high MSS CRC to germ-free mice bearing MSS CRC confers sensitivity to an …
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.
Lu Y, Yuan X, Wang M, He Z, Li H, Wang J, Li Q. Lu Y, et al. J Hematol Oncol. 2022 Apr 29;15(1):47. doi: 10.1186/s13045-022-01273-9. J Hematol Oncol. 2022. PMID: 35488243 Free PMC article. Review.
Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs). Decipheri …
Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate a …
Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy.
Phelps CM, Willis NB, Duan T, Lee AH, Zhang Y, Rodriguez J DM, Pandey SP, Laughlin CR, Rosen ABI, McPherson AC, Shapira JH, Randhawa SK, Hedden L, Richie TG, Wiechman HM, Bender MJ, Nemet I, Zöhrer PA, Gottschalk RA, Schmitz KH, Mullett SJ, Gelhaus SL, Davar D, Zarour HM, Hinterleitner R, Mossington T, Badger JH, Rodrigues RR, McCulloch JA, Lee STM, Wagner KH, Winter MG, Winter SE, Das J, Pierre JF, Trinchieri G, Meisel M. Phelps CM, et al. Cell. 2025 Oct 2;188(20):5680-5700.e28. doi: 10.1016/j.cell.2025.06.018. Epub 2025 Jul 9. Cell. 2025. PMID: 40639377 Free PMC article.
Exercise improves immune checkpoint inhibitor (ICI) efficacy in cancers such as melanoma; however, the mechanisms through which exercise mediates this antitumor effect remain obscure. ...
Exercise improves immune checkpoint inhibitor (ICI) efficacy in cancers such as melanoma; however, the mechanisms through which exerc …
Microbial metabolite FAD mobilizes adipocyte lipid remodeling to enhance cancer immunotherapy efficacy.
Tong T, Huang X, Li L, Hu M, Zhu X, Zhu B, Ma Y, Ning L, Jiang Y, Zhang Y, Zhou Y, Wang Z, Ding J, Zhao Y, Xuan B, Zhang Y, Xiao X, Fang JY, Hong J, Yin Y, Liu F, Chen H. Tong T, et al. Cell Metab. 2026 Mar 3;38(3):565-581.e5. doi: 10.1016/j.cmet.2025.12.012. Epub 2026 Jan 21. Cell Metab. 2026. PMID: 41570815
Crosstalk between gut microbiota and adipose tissue critically shapes immunotherapy responses in patients with cancer. An obesity-associated microbial signature enriched in riboflavin-producing taxa was identified, along with increased microbial riboflavin biosynthe …
Crosstalk between gut microbiota and adipose tissue critically shapes immunotherapy responses in patients with cancer. An obes …
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.
Duttagupta S, Messaoudene M, Hunter S, Desilets A, Jamal R, Mihalcioiu C, Belkaid W, Marcoux N, Fidelle M, Suissa D, Ponce M, Geiger M, Malo J, Piccinno G, Punčochář M, Filin A, Heidrich V, Rusu D, Mbaye B, Durand S, Ben Aissa I, Puller V, de Lahondès R, Blais N, Tehfe M, Owen S, Bélanger K, Parvathy SN, Shieh B, Raphael J, Lenehan J, Breadner D, Rothenstein J, Rozza N, Maillou J, Nili S, Prifti DK, Pinto F, Armanini F, Kim-Schulze S, Marron TU, Kroemer G, Derosa L, Zitvogel L, Silverman M, Segata N, Maleki Vareki S, Routy B, Elkrief A. Duttagupta S, et al. Nat Med. 2026 Apr;32(4):1337-1350. doi: 10.1038/s41591-025-04186-5. Epub 2026 Jan 28. Nat Med. 2026. PMID: 41606121 Free PMC article. Clinical Trial.
Immune checkpoint inhibitors (ICI) have improved outcomes for patients with non-small cell lung cancer (NSCLC) and melanoma, yet over half of patients exhibit primary resistance. Fecal microbiota transplantation (FMT) may overcome resistance to anti-programmed cell …
Immune checkpoint inhibitors (ICI) have improved outcomes for patients with non-small cell lung cancer (NSCLC) and melanoma, yet over …
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.
Huang J, Liu D, Wang Y, Liu L, Li J, Yuan J, Jiang Z, Jiang Z, Hsiao WW, Liu H, Khan I, Xie Y, Wu J, Xie Y, Zhang Y, Fu Y, Liao J, Wang W, Lai H, Shi A, Cai J, Luo L, Li R, Yao X, Fan X, Wu Q, Liu Z, Yan P, Lu J, Yang M, Wang L, Cao Y, Wei H, Leung EL. Huang J, et al. Gut. 2022 Apr;71(4):734-745. doi: 10.1136/gutjnl-2020-321031. Epub 2021 May 18. Gut. 2022. PMID: 34006584 Free PMC article.
OBJECTIVE: Programmed death 1 and its ligand 1 (PD-1/PD-L1) immunotherapy is promising for late-stage lung cancer treatment, however, the response rate needs to be improved. ...CONCLUSION: Our results demonstrate that GPs combined with alphaPD-1 mAb may be a new str …
OBJECTIVE: Programmed death 1 and its ligand 1 (PD-1/PD-L1) immunotherapy is promising for late-stage lung cancer treatment, h …
199 results